Traditional vaccine development is slow, taking 10-15 years, but human challenge studies can accelerate the process by up to five years. Human challenge studies can identify the most promising vaccine candidates early, so only the most promising ones are taken forward to large Phase III trials. AI, combined with data from human studies and lab automation, can revolutionize vaccine design, potentially enabling the creation of new vaccines within 100 days. 

We have the possibility to develop a new vaccine development paradigm and demonstrate it in EBV and other high promise targets. 

Skills:

• Vaccinology
• Clinical Research
• Bioinformatics
• Immunology
• Immune Diseases
• Neuroimmunology